The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Eisenmenger's Syndrome Clinical Trial

Official title: Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Status Completed

Clinical Trial Summary

Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Eisenmenger Complex
• Eisenmenger's Syndrome
• Heart Defects, Congenital
• Heart Diseases
• Syndrome

• NCT number: NCT01283958
• Study type: Observational
• Source: Gachon University Gil Medical Center
• Status: Completed
• Phase: N/A
• Start date: September 2007
• Completion date: May 2010